Market Overview

UPDATE: Piper Jaffray Downgrades Sequenom to Neutral, Lowers PT

Related SQNM
Wedbush Securities Expects In-Line Results For Sequenom
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups (Seeking Alpha)

In a report published Monday, Piper Jaffray & Co. downgraded its rating on Sequenom (NASDAQ: SQNM) from Overweight to Neutral, and lowered its price target from $6.50 to $5.00.

Piper Jaffray noted, “Recent management travels highlighted the recent capital raise, associated strength of their balance sheet, expanded menu and recent hiring of an additional 25 reps (now at 75) as their arsenal against competition. Management seems resigned to a protracted siege, intent to scale their tests delivered numbers (and hence better economics) as a way to pressure their smaller competitors. Separately, the company continues to have multiple contact with payers and although they recently reiterated their 2 large contracts by year end goal, our reimbursement experience suggests these discussions drag out. Bottom line: Sequenom is digging in for a long, likely expensive, battle and we are lowering our rating; preferring to sit this one out. We rate SQNM shares Neutral with a $5 price target (was $6.50).”

Sequenom closed on Friday at $3.94.

Latest Ratings for SQNM

Jun 2014William BlairUpgradesMarket PerformOutperform
Jan 2014Piper JaffrayDowngradesOverweightNeutral
Nov 2013Maxim GroupReiteratesBuy

View More Analyst Ratings for SQNM
View the Latest Analyst Ratings

Posted-In: Piper Jaffray & Co.Analyst Color Downgrades Analyst Ratings


Related Articles (SQNM)

Around the Web, We're Loving...